David Mischoulon, MD, PhD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

  • 39Articles
  • 256.8KReads
  • 2002–2026Active
  • 182Collaborators
  • 1.3KCitations

About

David Mischoulon, MD, PhD, is affiliated with the Department of Psychiatry at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. He has contributed to 39 articles published between 2002 and 2026 on topics including depression, bipolar disorder, complementary and alternative medicine, neurology, psychiatry, Alzheimer disease, dementia, and genetics. His frequent co-authors include Maurizio Fava, George I. Papakostas, Jonathan E. Alpert, Andrew A. Nierenberg, and Cristina Cusin.

Publications

PCC
Differentiating Bipolar and Other Psychiatric Disorders
Rounds in the General Hospital ▶ Video

Differentiating Bipolar and Other Psychiatric Disorders

May 12, 2026

Diagnosis of bipolar spectrum disorder is often complicated, as most patients present for care during depressive episodes, which are more frequent than hypomanic or manic episodes.
, , , et al
JCP
Investigation of Appetite Hormones Illustrates Current Limitations of Psychiatric Diagnosis
Commentary

Investigation of Appetite Hormones Illustrates Current Limitations of Psychiatric Diagnosis

April 9, 2025

Commenting on an article by Hsu and colleagues, Dr Mischoulon discusses the current state and future potential of biomarkers in the understanding and treatment of mood disorders.
JCP
Heated Yoga for Depression
Original Research

Heated Yoga for Depression

October 23, 2023

Approximately 1 heated yoga session per week for 8 weeks led to significantly greater reduction in depression symptoms than a waitlist control.
, , , et al
PCC
Management of Treatment-Resistant Depression in Primary Care
Rounds in the General Hospital

Management of Treatment-Resistant Depression in Primary Care

July 25, 2023

Novel and innovative clinical care pathways that integrate specialist care need to be implemented to address the burden of treatment-resistant depression in primary care.
, , , et al
JCP
Vitamin D3 and Omega-3 Fatty Acids for Depression Prevention
Original Research

Vitamin D3 and Omega-3 Fatty Acids for Depression Prevention

June 26, 2023

Although several lines of evidence suggest that vitamin D3 and omega-3 fatty acids promote mood health, neither supplement showed benefits for indicated and selective prevention of late-life depression.
, , , et al
JCP
Omega-3 Fatty Acids for MDD With High Inflammation
Original Research

Omega-3 Fatty Acids for MDD With High Inflammation

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.
, , , et al
JCP
Very Low-Level Transcranial Photobiomodulation for MDD
Original Research

Very Low-Level Transcranial Photobiomodulation for MDD

August 8, 2022

Transcranial photobiomodulation may be efficacious for major depressive disorder, but the optimal dose is not known. Here, a very low dose was studied to establish a threshold for lack...
, , , et al
JCP
Original Research

Ganaxolone for Persistent Depression

June 9, 2020

Postmenopausal women may be deficient in the neuroactive steroid allopregnanolone. This study examined oral ganaxolone, an allopregnanolone analog, as augmentation therapy in postmenopausal women with inadequate response to traditional...
, , , et al
PCC
Article

Metabolic Syndrome in Dutch Bipolar Patients

December 6, 2018

Metabolic syndrome is highly prevalent in patients with bipolar disorder. The authors of this study characterize the prevalence of metabolic syndrome among Dutch patients with bipolar disorder, identify factors...
, , , et al
PCC
Rounds in the General Hospital

Obstructive Sleep Apnea as a Complication of Bipolar Disorder and Its Treatment

November 30, 2017

First-line treatments for bipolar disorder are associated with multisystem side effects, especially weight gain, that predispose patients to obstructive sleep apnea among other complications. This article provides up-to-date information...
, , , et al
JCP
Review Article

Adenosylmethionine (SAMe) for Depression

June 28, 2017

Read a systematic review on S-adenosylmethionine (SAMe) for treatment of neuropsychiatric conditions, depression, and comorbid medical conditions.
, , , et al
JCP
Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe